BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2648 related articles for article (PubMed ID: 23792563)

  • 21. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
    Mehdi A; Riazalhosseini Y
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.
    Li DY; Lin FF; Li GP; Zeng FC
    Kaohsiung J Med Sci; 2021 Nov; 37(11):973-982. PubMed ID: 34337864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma.
    Buck MJ; Raaijmakers LM; Ramakrishnan S; Wang D; Valiyaparambil S; Liu S; Nowak NJ; Pili R
    Oncogene; 2014 Oct; 33(41):4961-5. PubMed ID: 24186201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
    Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
    Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetics of clear-cell renal cell carcinoma.
    Brugarolas J
    J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
    Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
    Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
    He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
    Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
    Feng C; Ding G; Jiang H; Ding Q; Wen H
    Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion.
    Dey N; Das F; Ghosh-Choudhury N; Mandal CC; Parekh DJ; Block K; Kasinath BS; Abboud HE; Choudhury GG
    PLoS One; 2012; 7(6):e37366. PubMed ID: 22685542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.
    Chen F; Zhang Y; Şenbabaoğlu Y; Ciriello G; Yang L; Reznik E; Shuch B; Micevic G; De Velasco G; Shinbrot E; Noble MS; Lu Y; Covington KR; Xi L; Drummond JA; Muzny D; Kang H; Lee J; Tamboli P; Reuter V; Shelley CS; Kaipparettu BA; Bottaro DP; Godwin AK; Gibbs RA; Getz G; Kucherlapati R; Park PJ; Sander C; Henske EP; Zhou JH; Kwiatkowski DJ; Ho TH; Choueiri TK; Hsieh JJ; Akbani R; Mills GB; Hakimi AA; Wheeler DA; Creighton CJ
    Cell Rep; 2016 Mar; 14(10):2476-89. PubMed ID: 26947078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN in Chromatin Remodeling.
    Yang J; Yin Y
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31570373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
    Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
    Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.
    Wang H; Zhang P; Lin C; Yu Q; Wu J; Wang L; Cui Y; Wang K; Gao Z; Li H
    PLoS One; 2015; 10(2):e114250. PubMed ID: 25714556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 133.